Correlation between macular edema and retinal sensitivity before and after anti-VEGF therapy for retinal vein occlusion

Correlation between macular edema and retinal sensitivity before and after anti-VEGF therapy for retinal vein occlusion - Macular edema volume and visual sensitivity for retinal vein occlusion

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011310

Enrollment

Registered

2013-07-30

Start date

2013-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal vein occlusion

Interventions

bevacizumav 6 month 1.25mg (0.05ml) 1 and over (pro re nata)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Case of macular edema due to retinal vein occlusion indicated for tratment of intravitreal bevacizumab

Exclusion criteria

Exclusion criteria: case without retinal disease except retinal vein occlusion

Design outcomes

Primary

Measure	Time frame
macular edema volume retinal sensitivity	—

Secondary

Measure	Time frame
visual acuity	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026